Ardelyx, Inc., a specialized biopharmaceutical company, develops and sells disruptive medicines for the treatment of cardio renal and gastrointestinal diseases in the United States and Asia Pacific. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program for the treatment of patients with hyperkalemia; RDX8940, an oral TGR5 agonist; RDX011, a NHE3 inhibitor; and RDX023 program for the development of gut-biased farnesoid X receptor agonists. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ARDX
CUSIPN/A
Phone510-745-1700
Debt
Debt-to-Equity Ratio0.30
Current Ratio14.21
Quick Ratio14.21
Price-To-Earnings
Trailing P/E Ratio-2.90
Forward P/E Ratio-2.52
P/E GrowthN/A
Sales & Book Value
Annual Sales$42 million
Price / Sales5.84
Cash FlowN/A
Price / CashN/A
Book Value$2.93 per share
Price / Book1.35
Profitability
EPS (Most Recent Fiscal Year)($1.36)
Net Income$-64,330,000.00
Net MarginsN/A
Return on Equity-35.76%
Return on Assets-29.70%
Miscellaneous
Employees75
Outstanding Shares62,050,000
Market Cap$199.93 million
Ardelyx (NASDAQ:ARDX) Frequently Asked Questions
What is Ardelyx's stock symbol?
Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."
How were Ardelyx's earnings last quarter?
Ardelyx Inc (NASDAQ:ARDX) issued its quarterly earnings data on Tuesday, August, 7th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.02. The biopharmaceutical company earned $0.03 million during the quarter. View Ardelyx's Earnings History.
When is Ardelyx's next earnings date?
What price target have analysts set for ARDX?
5 brokers have issued 1-year price targets for Ardelyx's shares. Their predictions range from $11.00 to $16.00. On average, they anticipate Ardelyx's stock price to reach $12.80 in the next twelve months. This suggests a possible upside of 224.1% from the stock's current price. View Analyst Price Targets for Ardelyx.
What is the consensus analysts' recommendation for Ardelyx?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ardelyx.
Who are some of Ardelyx's key competitors?
Some companies that are related to Ardelyx include OptiNose (OPTN), Dicerna Pharmaceuticals (DRNA), Cara Therapeutics (CARA), NuCana (NCNA), Inflarx (IFRX), Kura Oncology (KURA), Aptinyx (APTX), CymaBay Therapeutics (CBAY), Crinetics Pharmaceuticals (CRNX), Kiniksa Pharmaceuticals (KNSA), Epizyme (EPZM), Geron (GERN), ANI Pharmaceuticals Inc Common Stock (ANIP), Vectura Group (VEGPF) and Abeona Therapeutics (ABEO).
Who are Ardelyx's key executives?
Ardelyx's management team includes the folowing people:
- Mr. Michael G. Raab, Pres, CEO & Director (Age 53)
- Mr. David Rosenbaum, Chief Devel. Officer (Age 57)
- Mr. Mark E. Kaufmann, CFO & Treasurer (Age 50)
- Dr. Reginald Seeto, COO & Exec. VP (Age 46)
- Mr. Bryan Shaw, Chief Accounting Officer, VP and Controller (Age 64)
Has Ardelyx been receiving favorable news coverage?
Media headlines about ARDX stock have trended somewhat positive recently, according to Accern Sentiment. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ardelyx earned a coverage optimism score of 0.12 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 44.70 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days. View Recent Headlines for Ardelyx.
Who are Ardelyx's major shareholders?
Ardelyx's stock is owned by many different of retail and institutional investors. Top institutional investors include NEW ENTERPRISE ASSOCIATES 12, LIMITED PARTNERSHIP Total Shares: 16,736,044 (27.20%), NEW ENTERPRISE ASSOCIATES 12, LIMITED PARTNERSHIPTotal Shares:16,736,044 (27.20%), NEA Management Company LLC (32.22%), BlackRock Inc. (7.52%), Dimensional Fund Advisors LP (2.72%) and Millennium Management LLC (2.28%). Company insiders that own Ardelyx stock include David P Rosenbaum, Elizabeth A Grammer, Forest Baskett, Gordon Ringold, Jeffrey W Jacobs, Jeremy S Caldwell and Reginald Seeto. View Institutional Ownership Trends for Ardelyx.
Which major investors are selling Ardelyx stock?
ARDX stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp. Company insiders that have sold Ardelyx company stock in the last year include Forest Baskett and Reginald Seeto. View Insider Buying and Selling for Ardelyx.
Which major investors are buying Ardelyx stock?
ARDX stock was bought by a variety of institutional investors in the last quarter, including NEA Management Company LLC, BlackRock Inc., Millennium Management LLC, Renaissance Technologies LLC, Dimensional Fund Advisors LP, GSA Capital Partners LLP, DAFNA Capital Management LLC and Alambic Investment Management L.P.. View Insider Buying and Selling for Ardelyx.
How do I buy shares of Ardelyx?
Shares of ARDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ardelyx's stock price today?
One share of ARDX stock can currently be purchased for approximately $3.95.
How big of a company is Ardelyx?
Ardelyx has a market capitalization of $199.93 million and generates $42 million in revenue each year. The biopharmaceutical company earns $-64,330,000.00 in net income (profit) each year or ($1.36) on an earnings per share basis. Ardelyx employs 75 workers across the globe.
How can I contact Ardelyx?
Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The biopharmaceutical company can be reached via phone at 510-745-1700 or via email at [email protected]
MarketBeat Community Rating for Ardelyx (NASDAQ ARDX)
MarketBeat's community ratings are surveys of what our community members think about Ardelyx and other stocks. Vote "Outperform" if you believe ARDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
